The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
Open accessAbstract
A 46-year-old woman with relapsing-remitting multiple sclerosis died from progressive multifocal leukoencephalopathy (PML) after having received 37 doses of natalizumab (300 mg every four weeks) as part of a clinical trial of natalizumab and interferon beta-1a.PML was diagnosed on the basis of the finding of JC viral DNA in cerebrospinal fluid on polymerase-chain-reaction assay and was confirmed at autopsy.Nearly every tissue section from bilateral cerebral hemispheres contained either macroscopic or microscopic PML lesions.There was extensive tissue destruction and cavitation in the left frontoparietal area, large numbers of bizarre astrocytes, and inclusion-bearing oligodendrocytes, which were positive for JC virus DNA on in situ hybridization.rogressive multifocal leukoencephalopathy (pml), a demyelinating disease of the central nervous system (CNS), is associated with high rates of morbidity and mortality and occurs almost exclusively in immunocompromised patients.1 We describe a patient with multiple sclerosis who died of PML after receiving natalizumab (Tysabri, Biogen Idec) as part of a clinical trial conducted to test the safety and efficacy of natalizumab in combination with interferon beta-1a (Avonex, Biogen Idec) in the treatment of relapsing-remitting multiple sclerosis.To our knowledge, there have been no prior reports of the concomitant association of multiple sclerosis and PML.Natalizumab is a humanized monoclonal antibody against a 4 integrins that was recently introduced for the treatment of multiple sclerosis.The drug was withdrawn from the market after reports of the development of PML in two patients with multiple sclerosis who were receiving natalizumab and interferon beta-1a in clinical trials.An additional case of PML, in a patient receiving natalizumab for the treatment of Crohn's disease, is described elsewhere in this issue of the Journal . 2 A 41-year-old, right-handed woman began to have numbness and burning pain in her right foot and leg and tingling numbness and clumsiness in her right hand in June 1999.She had a history of migraine and transient numbness of the left hand.A neurologic examination revealed increased tone on her right side and generalized hyperreflexia (3+) with normal plantar responses.In September 1999, magnetic resonance imaging (MRI) with contrast medium showed four small, nonenhancing foci of increased signal in the summary p case report
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Natalizumab for Active Crohn's Disease
Ghosh, S., Goldin, E., Gordon, F. H., Malchow, H. A., Rask-Madsen, J., Rutgeerts, P., Vyhnálek, P., Zádorová, Z., Palmer, T., & Donoghue, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020732 · Cited by 808
Knowles, W. A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D. W. G., & Miller, E. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10450 · Cited by 586
Anti-α4 integrin therapy for multiple sclerosis: Mechanisms and rationale
Rice, G. P. A., Hartung, H.-P., & Calabresi, P. A. (2005) · Neurology · doi:10.1212/01.wnl.0000158329.30470.d0 · Cited by 305
α4Integrins as Therapeutic Targets in Autoimmune Disease
von Andrian, U. H., & Engelhardt, B. (2003) · New England Journal of Medicine · doi:10.1056/nejme020157 · Cited by 276
Kent, S. J., Karlik, S. J., Cannon, C., Hines, D. K., Yednock, T. A., Fritz, L. C., & Horner, H. C. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)00165-k · Cited by 201
Goldberg, S. L., Pecora, A. L., Alter, R. S., Kroll, M. S., Rowley, S. D., Waintraub, S. E., Imrit, K., & Preti, R. A. (2002) · Blood · doi:10.1182/blood.v99.4.1486 · Cited by 190
Gasnault, J., Kahraman, M., de Herve, M.-G. D. G., Duralı, D., Delfraissy, J., & Taoufik, Y. (2003) · AIDS · doi:10.1097/00002030-200307040-00004 · Cited by 130
Cited by
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Neutrophils and immunity: challenges and opportunities
Nathan, C. (2006) · Nature reviews. Immunology · doi:10.1038/nri1785 · Cited by 2,971
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Metadata
- Authors
- Kleinschmidt-DeMasters, B. K., & Tyler, K. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-28
- Volume
- 353
- Issue
- 4
- Pages
- 369-374
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1970547229
- Cited by
- 1,072
- References
- 10
- FWCI
- 47.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.